Switching from intravenous to subcutaneous Infliximab in patients with immune mediated diseases in clinical remission

被引：0

作者：

Viazis, N. ^{[1
]}

Karamanakos, A. ^{[2
]}

Mousourakis, K. ^{[3
]}

Christidou, A. ^{[4
]}

Fousekis, F. ^{[5
]}

Mpakogiannis, K. ^{[5
]}

Koukoudis, A. ^{[5
]}

Katsanos, K. ^{[5
]}

Christodoulou, D. ^{[5
]}

Cheila, M. ^{[6
]}

Tzouvala, M. ^{[7
]}

Zacharopoulou, E. ^{[7
]}

Palatianou, M. ^{[7
]}

Giouleme, O. ^{[8
]}

Katsoula, A. ^{[8
]}

Liatsos, C. ^{[9
]}

Kyriakos, N. ^{[9
]}

Zampeli, E. ^{[10
]}

Papathanasiou, E. ^{[10
]}

Theodoropoulou, A. ^{[11
]}

Karmiris, K. ^{[12
]}

Psaroudakis, I ^{[13
]}

Tribonias, G. ^{[14
]}

Gazi, S. ^{[15
]}

Mole, E. ^{[15
]}

Dimitroulas, T. ^{[16
]}

Koutsianas, C. ^{[17
]}

Vasilopoulos, D. ^{[17
]}

Fragoulis, G. ^{[18
]}

Michalakeas, N. ^{[18
]}

Papagoras, C. ^{[19
]}

Panagakis, P. ^{[20
]}

Papoutsaki, M. ^{[20
]}

Chasapi, V ^{[20
]}

Stratigos, A. ^{[20
]}

Katsikas, G. ^{[21
]}

机构：

[1] Evangelismos Gen Hosp, Gastroenterol, Athens, Greece

[2] Evangelismos Med Ctr, Rheumatol, Athens, Greece

[3] Evangelismos, Gastroenterol, Athens, Greece

[4] Evangelismos Med Ctr, Gastroenterol, Athens, Greece

[5] Univ Hosp Ioannina, Gastroenterol, Ioannina, Greece

[6] Gen Hosp Evangelismos, Rheumatol, Athens, Greece

[7] Gen Hosp Nikaia Agios Panteleimon, Gastroenterol, Athens, Greece

[8] Second Propedeut Dept Internal Med Hippokrat, Gastroenterol, Thessaloniki, Greece

[9] 401 Gen Mil Hosp, Gastroenterol, Athens, Greece

[10] Gen Hosp Alexandra, Gastroenterol, Athens, Greece

[11] Gen Hosp Venizeleio, Gastroenterol, Hrakleion, Greece

[12] Gen Hosp Venizeleio, Gastroenterol, Iraklion, Greece

[13] Gen Hosp Venizeleio, Gastroenterol, Herakleiomn, Greece

[14] Erythros Stavros, Gastroenterol, Athens, Greece

[15] Gen Hosp Attica, Rheumatol, Athens, Greece

[16] Gen Hosp Ippokrateio, Rheumatol, Thessaloniki, Greece

[17] Gen Hosp Ippokrateio, Rheumatol, Athens, Greece

[18] Joint Acad Rheumatol Ctr Laiko Gen Hosp, Rheumatol, Athens, Greece

[19] Univ Hosp Alexandroupolis, Rheumatol, Alexandroupolis, Greece

[20] Andreas Syggros Hosp, Dermatol, Athens, Greece

[21] Evangelismos Gen Hosp, Rheumatol, Athens, Greece

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1120

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0946

引用

页码：i1773 / i1773

页数：1

共 50 条

[41] Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission
Viazis, N.
Pontas, C.
Manolakis, A.
Karampekos, G.
Tsoukali, E.
Galanopoulos, M.
Koustenis, K.
Archavlis, E.
Christidou, A.
Gazouli, M.
Mantzaris, G. J.
ACTA GASTRO-ENTEROLOGICA BELGICA, 2021, 84 (03) : 423 - 428
[42] Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Rajab, Fatima
Mujahid, Aleena
Rajab, Hadia
Alvi, Abdullah
DIGESTIVE AND LIVER DISEASE, 2024, 56 (04) : 716 - 717
[43] Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
Buisson, A.
Nachury, M.
Bazoge, M.
Yzet, C.
Wils, P.
Dodel, M.
Coban, D.
Pereira, B.
Fumery, M.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1364 - I1364
[44] Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
Cummings, F.
Buisson, A.
Smith, P. J.
Rahmany, S.
Subramanian, S.
Kwon, B.
Park, S.
Lee, Y. N.
Fumery, M.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1332 - I1333
[45] EFFECTIVENESS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: A COMBINED ANALYSIS OF REAL-WORLD EVIDENCE
Cummings, Fraser
Buisson, Anthony
Smith, Philip J.
Rahmany, Sohail
Subramanian, Sreedhar
Kwon, Buki
Park, Soyeon
Lee, Young Nam
Fumery, Mathurin
GASTROENTEROLOGY, 2024, 166 (05) : S1144 - S1144
[46] EFFICACY AND SAFETY OF ELECTIVE SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
Smith, Philip J.
Storey, Daniel
Gregg, Belle
Critchley, Lisa
Stenson, June
Kneebone, Andrew
Rimmer, Tracy
Burke, Stevena
Teoh, Wan Yi
Vazeille, Stephan
Serna, Solange
Bond, Ashley
Steel, Alan
Dibb, Martyn
Collins, Paul
Derbyshire, Edmund
Bodger, Keith
Probert, Christopher
Verma, Ajay
Subramanian, Sreedhar
GUT, 2021, 70 : A84 - A84
[47] Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with Inflammatory Bowel Disease. One year follow-up
Andres Pascual, L.
Arias Garcia, L.
Saiz Chumillas, R. M.
Chivato Martin-Falquina, I.
Sicilia Aladren, B.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1083 - I1084
[48] Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Lee, Bokyeong
Kim, Minjee
Kim, Eun Ran
Hong, Sung Noh
Chang, Dong Kyung
Kim, Young-Ho
SCIENTIFIC REPORTS, 2024, 14 (01):
[49] Effectiveness of Switching to Subcutaneous Infliximab in Inflammatory Bowel Disease Patients with Inadequate Biochemical Response during Intravenous Administration
Kim, M.
Lee, B.
Kim, E. R.
Hong, S. N.
Chang, D. K.
Kim, Y. H.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1443 - i1444
[50] Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab
Husman, Julia
Cerna, Karin
Matthes, Katja
Gilger, Maximilian
Arsova, Maia
Schmidt, Alexandra
Winzer, Nadia
Brosch, Anna-Magdalena
Brinkmann, Franz
Hampe, Jochen
Zeissig, Sebastian
Lukas, Milan
Schmelz, Renate
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2024, 39 (01)

← 1 2 3 4 5 →